Cantor Fitzgerald Reiterates Overweight on Denali Therapeutics, Maintains $35 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Denali Therapeutics, maintaining a $35 price target.
September 09, 2024 | 3:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Denali Therapeutics, maintaining a $35 price target.
The reiteration of an Overweight rating and maintenance of a $35 price target by a reputable analyst can positively influence investor sentiment and potentially lead to a short-term increase in DNLI's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100